Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average cost of $1.50 per share, with a total value of $150,000.00. Following the completion of the acquisition, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at approximately $4,603,426.50. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, December 9th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.59 per share, with a total value of $79,500.00.
  • On Thursday, December 5th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.62 per share, with a total value of $81,000.00.
  • On Monday, December 2nd, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.56 per share, with a total value of $78,000.00.
  • On Tuesday, November 26th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.55 per share, with a total value of $155,000.00.
  • On Monday, November 18th, Phillip Md Et Al Frost bought 100,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.48 per share, with a total value of $148,000.00.
  • On Tuesday, November 12th, Phillip Md Et Al Frost bought 200,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.44 per share, with a total value of $288,000.00.
  • On Friday, November 8th, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.48 per share, with a total value of $74,000.00.
  • On Wednesday, November 6th, Phillip Md Et Al Frost bought 350,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.49 per share, with a total value of $521,500.00.
  • On Thursday, October 31st, Phillip Md Et Al Frost bought 50,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.43 per share, with a total value of $71,500.00.
  • On Tuesday, October 29th, Phillip Md Et Al Frost bought 200,000 shares of Opko Health stock. The stock was acquired at an average cost of $1.47 per share, with a total value of $294,000.00.

OPK traded up $0.01 during trading on Friday, reaching $1.54. The company had a trading volume of 27,726 shares, compared to its average volume of 4,159,409. The stock has a market cap of $1.01 billion, a P/E ratio of -6.16 and a beta of 2.20. The business has a 50 day simple moving average of $1.54 and a 200-day simple moving average of $1.90. Opko Health Inc. has a 52 week low of $1.33 and a 52 week high of $3.93. The company has a quick ratio of 0.90, a current ratio of 1.08 and a debt-to-equity ratio of 0.14.

Opko Health (NASDAQ:OPK) last issued its quarterly earnings results on Tuesday, November 5th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). The company had revenue of $228.80 million during the quarter, compared to the consensus estimate of $225.40 million. Opko Health had a negative return on equity of 14.42% and a negative net margin of 30.98%. The firm’s quarterly revenue was down 8.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.05) earnings per share. As a group, equities research analysts expect that Opko Health Inc. will post -0.43 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Cito Capital Group LLC lifted its position in shares of Opko Health by 5.1% during the second quarter. Cito Capital Group LLC now owns 184,000 shares of the biotechnology company’s stock worth $449,000 after purchasing an additional 9,000 shares during the last quarter. Commonwealth Equity Services LLC lifted its position in shares of Opko Health by 2.4% during the third quarter. Commonwealth Equity Services LLC now owns 420,879 shares of the biotechnology company’s stock worth $879,000 after purchasing an additional 9,900 shares during the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. lifted its position in shares of Opko Health by 100.0% during the second quarter. GABELLI & Co INVESTMENT ADVISERS INC. now owns 20,000 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 10,000 shares during the last quarter. Alpha Cubed Investments LLC bought a new stake in shares of Opko Health during the third quarter worth $25,000. Finally, Aperio Group LLC lifted its position in shares of Opko Health by 21.0% during the second quarter. Aperio Group LLC now owns 72,789 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 12,631 shares during the last quarter. Institutional investors own 21.61% of the company’s stock.

A number of research analysts recently weighed in on OPK shares. BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, November 21st. Piper Jaffray Companies began coverage on Opko Health in a research report on Monday, November 25th. They issued an “overweight” rating and a $2.50 price target for the company. Zacks Investment Research upgraded Opko Health from a “hold” rating to a “buy” rating and set a $2.00 price target for the company in a research report on Friday, October 18th. Finally, Barrington Research restated a “buy” rating and issued a $4.00 price target on shares of Opko Health in a research report on Thursday, September 12th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $2.83.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.

Featured Story: Cash Asset Ratio

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.